… The DAPA‐CKD trial required that all patients be treated … DAPA‐CKD trial, we aimed to
examine whether baseline use of cardiovascular medications modified the effects of dapagliflozin …

… In this prespecified analyses of the DAPA-CKD trial, we assessed the effect of dapagliflozin
on eGFR slope by establishing the effect of dapagliflozin on changes in eGFR during the …

… DAPA-HF, we used previously described methods to enable estimation of the projected
long-term treatment effects of dapagliflozin … treatment effect of dapagliflozin compared with …

… , we examined the timing of onset of clinical benefit with dapagliflozin in the DAPA-HF trial. …
In this analysis from the DAPA-HF trial, we found that the clinical benefit of dapagliflozin for …

… was observed across the broad range of LVEF for CVM and hospitalization for HF (HHF). To
… from the DAPA-HF and DELIVER trials to explore the cost-effectiveness of dapagliflozin as a …

… In this prespecified subgroup analysis of the DAPA-CKD trial, we show beneficial effects
of dapagliflozin on kidney and cardiovascular end points in patients with stage 4 CKD at …

… outcomes and the effects of dapagliflozin in patients with HF with and without sleep apnea
in a pooled analysis of 2 trials comparing dapagliflozin to placebo in HFrEF (DAPA-HF trial) …

… In this prespecified analysis of the DAPA-CKD trial, we demonstrate that the effects of
dapagliflozin on kidney failure, heart failure, and mortality outcomes were consistent regardless of …

… individual participant‐level data from DELIVER and DAPA‐HF, we found that the addition
of dapagliflozin to standard of care in patients with HF across the full spectrum of EF was of …

… In conclusion, the findings of the post hoc analysis of DAPA-HF that demonstrate a positive
effect of dapagliflozin on the composite outcome of any serious VA, resuscitated cardiac arrest…